• レポートコード:MRC2403B300 • 出版社/出版日:Transparency Market Research / 2024年1月 • レポート形態:英文、PDF、250ページ • 納品方法:受注後3営業日 • 産業分類:医療 |
Single User | ¥869,250 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,319,250 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
獣医分子診断市場 - レポートの範囲TMRの調査レポート「世界の獣医分子診断市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の獣医分子診断市場の収益を提供しています。また、2023年から2031年までの世界の獣医分子診断市場の複合年間成長率(CAGR %)も掲載しています。 本レポートは広範な調査を経て作成された。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連文書を参照し、獣医分子診断市場を理解しました。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の獣医分子診断市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界の動物用分子診断市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場プレイヤーだけでなく、世界の動物用分子診断市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートでは、世界の獣医分子診断市場の競争環境について掘り下げています。世界の獣医分子診断市場で事業を展開する主要企業が特定され、その各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の動物用分子診断市場におけるプレイヤーの属性です。 動物用分子診断の世界市場レポートで回答された主な質問 - 予測期間中の全地域におけるウェアラブル注射器による売上/収益は? - 世界の獣医分子診断市場におけるビジネスチャンスは? - 市場の主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは? - 世界市場で事業を展開する各企業の市場ポジションは? 獣医分子診断市場 - 調査目的と調査アプローチ 獣医分子診断の世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品承認に関する規制シナリオについて詳細に解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えます。また、過去と予測期間末の主要セグメントの市場シェアの比較も可能です。 本レポートでは、世界の獣医分子診断市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の獣医分子診断市場への投資について、十分な情報に基づいたビジネス上の意思決定を行うことができます。 |
1. 序論
2. 仮定・調査手法
3. エグゼクティブサマリー:世界の獣医分子診断市場
4. 市場概要
5. 主要インサイト
6. 世界の獣医分子診断市場分析・予測:製品タイプ別
7. 世界の獣医分子診断市場分析・予測:技術別
8. 世界の獣医分子診断市場分析・予測:疾患タイプ別
9. 世界の獣医分子診断市場分析・予測:動物別
10. 世界の獣医分子診断市場分析・予測:エンドユーザー別
11. 世界の獣医分子診断市場分析・予測:地域別
12. 北米の獣医分子診断市場分析・予測
13. ヨーロッパの獣医分子診断市場分析・予測
14. アジア太平洋の獣医分子診断市場分析・予測
15. 中南米の獣医分子診断市場分析・予測
16. 中東/アフリカの獣医分子診断市場分析・予測
17. 競争状況
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Veterinary Molecular Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Instruments & Software
6.3.2. Kits & Reagents
6.3.3. Services
6.4. Market Attractiveness, by Product Type
7. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Technology
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. Conventional PCR
7.3.2. Singleplex PCR
7.3.3. Multiplex PCR
7.3.4. Real-time PCR
7.3.5. Others
7.3.6. 7.4 Market Attractiveness, by Technology
8. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, By Disease Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Disease Type, 2017–2031
8.3.1. Vector-borne Diseases
8.3.2. Respiratory Pathogens
8.3.3. Diarrhea Pathogens
8.3.4. Others
8.4. Market Attractiveness, By Disease Type
9. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Animal Type
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Animal Type, 2017–2031
9.3.1. Companion Animal
9.3.2. Livestock Animal
9.4. Market Attractiveness, by Animal Type
10. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by End-user
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals/Clinics
10.3.2. Reference Laboratories
10.4. Market Attractiveness, by End-user
11. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Veterinary Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Instruments & Software
12.2.2. Kits & Reagents
12.2.3. Services
12.3. Market Attractiveness, by Product Type
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. Conventional PCR
12.4.2. Singleplex PCR
12.4.3. Multiplex PCR
12.4.4. Real-time PCR
12.4.5. Others
12.5. Market Attractiveness, by Technology
12.6. Market Value Forecast, By Disease Type, 2017–2031
12.6.1. Vector-borne Diseases
12.6.2. Respiratory Pathogens
12.6.3. Diarrhea Pathogens
12.6.4. Others
12.7. Market Attractiveness, By Disease Type
12.8. Market Value Forecast, by Animal Type, 2017–2031
12.8.1. Companion Animal
12.8.2. Livestock Animal
12.9. Market Attractiveness, by Animal Type
12.10. Market Value Forecast, by User End-user, 2017–2031
12.10.1. Hospitals/Clinics
12.10.2. Reference Laboratories
12.11. Market Attractiveness, by End-user
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Product Type
12.13.2. By Technology
12.13.3. By Disease Type
12.13.4. By Animal Type
12.13.5. By End-user
12.13.6. By Country
13. Europe Veterinary Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Instruments & Software
13.2.2. Kits & Reagents
13.2.3. Services
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. Conventional PCR
13.4.2. Singleplex PCR
13.4.3. Multiplex PCR
13.4.4. Real-time PCR
13.4.5. Others
13.5. Market Attractiveness, by Technology
13.6. Market Value Forecast, By Disease Type, 2017–2031
13.6.1. Vector-borne Diseases
13.6.2. Respiratory Pathogens
13.6.3. Diarrhea Pathogens
13.6.4. Others
13.7. Market Attractiveness, By Disease Type
13.8. Market Value Forecast, by Animal Type, 2017–2031
13.8.1. Companion Animal
13.8.2. Livestock Animal
13.9. Market Attractiveness, by Animal Type
13.10. Market Value Forecast, by User End-user, 2017–2031
13.10.1. Hospitals/Clinics
13.10.2. Reference Laboratories
13.11. Market Attractiveness, by End-user
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Product Type
13.13.2. By Technology
13.13.3. By Disease Type
13.13.4. By Animal Type
13.13.5. By End-user
13.13.6. By Country/Sub-region
14. Asia Pacific Veterinary Molecular Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2031
14.2.1. Instruments & Software
14.2.2. Kits & Reagents
14.2.3. Services
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Technology, 2017–2031
14.4.1. Conventional PCR
14.4.2. Singleplex PCR
14.4.3. Multiplex PCR
14.4.4. Real-time PCR
14.4.5. Others
14.5. Market Attractiveness, by Technology
14.6. Market Value Forecast, By Disease Type, 2017–2031
14.6.1. Vector-borne Diseases
14.6.2. Respiratory Pathogens
14.6.3. Diarrhea Pathogens
14.6.4. Others
14.7. Market Attractiveness, By Disease Type
14.8. Market Value Forecast, by Animal Type, 2017–2031
14.8.1. Companion Animal
14.8.2. Livestock Animal
14.9. Market Attractiveness, by Animal Type
14.10. Market Value Forecast, by User End-user, 2017–2031
14.10.1. Hospitals/Clinics
14.10.2. Reference Laboratories
14.11. Market Attractiveness, by End-user
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Product Type
14.13.2. By Technology
14.13.3. By Disease Type
14.13.4. By Animal Type
14.13.5. By End-user
14.13.6. By Country/Sub-region
15. Latin America Veterinary Molecular Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017–2031
15.2.1. Instruments & Software
15.2.2. Kits & Reagents
15.2.3. Services
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Technology, 2017–2031
15.4.1. Conventional PCR
15.4.2. Singleplex PCR
15.4.3. Multiplex PCR
15.4.4. Real-time PCR
15.4.5. Others
15.5. Market Attractiveness, by Technology
15.6. Market Value Forecast, By Disease Type, 2017–2031
15.6.1. Vector-borne Diseases
15.6.2. Respiratory Pathogens
15.6.3. Diarrhea Pathogens
15.6.4. Others
15.7. Market Attractiveness, By Disease Type
15.8. Market Value Forecast, by Animal Type, 2017–2031
15.8.1. Companion Animal
15.8.2. Livestock Animal
15.9. Market Attractiveness, by Animal Type
15.10. Market Value Forecast, by User End-user, 2017–2031
15.10.1. Hospitals/Clinics
15.10.2. Reference Laboratories
15.11. Market Attractiveness, by End-user
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Product Type
15.13.2. By Technology
15.13.3. By Disease Type
15.13.4. By Animal Type
15.13.5. By End-user
15.13.6. By Country/Sub-region
16. Middle East & Africa Veterinary Molecular Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Type, 2017–2031
16.2.1. Instruments & Software
16.2.2. Kits & Reagents
16.2.3. Services
16.3. Market Attractiveness, by Product Type
16.4. Market Value Forecast, by Technology, 2017–2031
16.4.1. Conventional PCR
16.4.2. Singleplex PCR
16.4.3. Multiplex PCR
16.4.4. Real-time PCR
16.4.5. Others
16.5. Market Attractiveness, by Technology
16.6. Market Value Forecast, By Disease Type, 2017–2031
16.6.1. Vector-borne Diseases
16.6.2. Respiratory Pathogens
16.6.3. Diarrhea Pathogens
16.6.4. Others
16.7. Market Attractiveness, By Disease Type
16.8. Market Value Forecast, by Animal Type, 2017–2031
16.8.1. Companion Animal
16.8.2. Livestock Animal
16.9. Market Attractiveness, by Animal Type
16.10. Market Value Forecast, by User End-user, 2017–2031
16.10.1. Hospitals/Clinics
16.10.2. Reference Laboratories
16.11. Market Attractiveness, by End-user
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Product Type
16.13.2. By Technology
16.13.3. By Disease Type
16.13.4. By Animal Type
16.13.5. By End-user
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. IDEXX Laboratories, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Thermo Fisher Scientific, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Zoetis, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Neogen Corporation
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. bioMérieux SA
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. QIAGEN N.V.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Biomedica Medizinprodukte GmbH
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Bioneer
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Mars, Incorporated
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Innovative Diagnostics
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview